Umoja: Umoja Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Find Momentum That Delivers with Edge+ Not all "hot stocks" are winners, but Tim Melvin's Edge+ can help you find the ones that count. Unlock picks with real staying power by tapping into decades of proven research. Upgrade now and take advantage of his guidance on your portfolio's next big winners. SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025, in San Francisco, CA. Presentation Date/Time : Wednesday, January 15, 2025 at 2:30 p.m. PT Presentation Location : Golden Gate (32nd Floor) The Westin Presenting Speaker : Andrew Scharenberg, M.D, co-founder and Chief Executive Officer About Umoja Biopharma Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja's VivoVec in vivo gene delivery technology empowers a patient's own immune system to fight disease. Enabling its core technology is the Company's state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/ . Investors Grace Kim, PhD Head of Investor Relations grace.kim@umoja-biopharma.com Media Matt Wright Real Chemistry mwright@realchemistry.com © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.